Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease
AUTOR(ES)
Hong, Ji Young, Jang, Sun Hee, Kim, Song Yee, Chung, Kyung Soo, Song, Joo Han, Park, Moo Suk, Kim, Young Sam, Kim, Se Kyu, Chang, Joon, Kang, Young Ae
FONTE
Braz J Infect Dis
DATA DE PUBLICAÇÃO
2016-02
RESUMO
Abstract Increased serum CA 19-9 levels in patients with nonmalignant diseases have been investigated in previous reports. This study evaluates the clinical significance of serum CA 19-9 elevation in pulmonary nontuberculous mycobacterial disease and pulmonary tuberculosis. The median CA 19-9 level was higher in patients with pulmonary nontuberculous mycobacterial disease than in patients with pulmonary tuberculosis (pulmonary nontuberculous mycobacterial disease: 13.80, tuberculosis: 5.85, p < 0.001). A multivariate logistic regression analysis performed in this study showed that Mycobacterium abscessus (OR 9.97, 95% CI: 1.58, 62.80; p = 0.014) and active phase of pulmonary nontuberculous mycobacterial disease (OR 12.18, 95% CI: 1.07, 138.36, p = 0.044) were found to be risk factors for serum CA 19-9 elevation in pulmonary nontuberculous mycobacterial disease. The serum CA 19-9 levels showed a tendency to decrease during successful treatment of pulmonary nontuberculous mycobacterial disease but not in pulmonary tuberculosis. These findings suggest that CA 19-9 may be a useful marker for monitoring therapeutic responses in pulmonary nontuberculous mycobacterial disease, although it is not pulmonary nontuberculous mycobacterial disease-specific marker.
Documentos Relacionados
- Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.
- CA 19-9 levels in patients with acute pancreatitis due to gallstone and metabolic/toxic reasons
- Comparison of Urinary and Serum CA 19-9 as Markers of Early Stage Urothelial Carcinoma
- CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
- Prognostic value of CA 19.9 levels in colorectal cancer.